Humans ; Class I Phosphatidylinositol 3-Kinases/genetics* ; Breast Neoplasms/diagnosis* ; Mutation ; Female ; China ; DNA Mutational Analysis/methods* ; Genetic Testing/standards*

Humans ; Colorectal Neoplasms/pathology* ; Pathology, Molecular/methods* ; Biomarkers, Tumor/genetics* ; Genetic Testing ; China

Humans ; Glioma/metabolism* ; Consensus ; China ; Brain Neoplasms/pathology* ; Pathology, Molecular

Humans ; Ovarian Neoplasms/metabolism* ; Female ; Biomarkers, Tumor/metabolism* ; Mutation

Humans ; Consensus ; High-Throughput Nucleotide Sequencing/standards* ; Neoplasms/diagnosis* ; Quality Control ; Sequence Analysis, DNA/methods* ; Sequence Analysis, RNA/methods*

Humans ; Thyroid Neoplasms/metabolism* ; Consensus ; Thyroidectomy ; China ; Immunohistochemistry ; Postoperative Period

Humans ; Biomarkers, Tumor/metabolism* ; Claudins/analysis* ; Consensus ; Immunohistochemistry/methods* ; Stomach Neoplasms/diagnosis*

Humans ; Ovarian Neoplasms/drug therapy* ; Folate Receptor 1/metabolism* ; Female ; Immunohistochemistry/standards* ; Consensus ; Biomarkers, Tumor/metabolism* ; Fallopian Tube Neoplasms/pathology*

High-grade endometrial stromal sarcoma(HGESS)is a rare but highly aggressive malignant tumor that poses a significant threat to women's reproductive health.It is associated with a poor clinical prognosis due to its high malignancy.HGESS exhibits diverse pathological morphologies,lacks specific immunohistochemical markers,and demonstrates various genetic alterations.These factors contribute to the challenges in achieving a definitive diagnosis,making accurate identification and diagnosis of this lesion particularly difficult.This article reviews the clinicopathologi-cal features,molecular characteristics,and key points for differential diagnosis of HGESS,aiming to enhance under-standing and awareness of this disease among clinicians and pathologists.

Ovarian seromucinous tumors are a group of ovarian epithelial tumors that primarily affect young women of childbearing age.The nomenclature and classification of these tumors undergone a complex historical evolution.Due to their diverse and complex morphological features,pathologists often encountered difficulties in applying diagnostic criteria.As a result,underdiagnosis and misdiagnosis were common in current clinical practice,which may even affect the choice of treatment for patients.This article aims to provide a detailed account of the historical changes in the no-menclature of ovarian seromucinous tumors,the common diagnostic challenges encountered in current clinical practice and their corresponding strategies,as well as to explore potential future research directions.It is hoped that this will enhance the understanding of these diseases among pathologists and gynecologists,and provide guidance for the formu-lation of appropriate treatment strategies and further scientific research.